Shares of QuidelOrtho Corporation (NASDAQ:QDEL – Get Free Report) have been given a consensus rating of “Reduce” by the six ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating and four have issued a hold rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $13.6250.
A number of analysts have issued reports on QDEL shares. Citigroup raised their target price on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Wall Street Zen upgraded shares of QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. Jefferies Financial Group restated a “hold” rating on shares of QuidelOrtho in a research report on Monday, June 29th. UBS Group reaffirmed a “neutral” rating and set a $12.00 target price on shares of QuidelOrtho in a research note on Thursday, May 7th. Finally, Zacks Research upgraded shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Monday, June 15th.
Read Our Latest Research Report on QDEL
QuidelOrtho Trading Up 1.2%
QuidelOrtho (NASDAQ:QDEL – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). The business had revenue of $619.80 million for the quarter, compared to analysts’ expectations of $665.23 million. QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.QuidelOrtho’s quarterly revenue was down 10.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.74 EPS. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Research analysts expect that QuidelOrtho will post 1.87 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. increased its stake in QuidelOrtho by 7.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,832,098 shares of the company’s stock worth $337,925,000 after acquiring an additional 819,908 shares during the last quarter. Invesco Ltd. raised its position in QuidelOrtho by 19.4% in the fourth quarter. Invesco Ltd. now owns 3,470,656 shares of the company’s stock valued at $99,122,000 after purchasing an additional 563,893 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of QuidelOrtho by 7.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,048,768 shares of the company’s stock valued at $50,085,000 after purchasing an additional 212,481 shares during the last quarter. State Street Corp lifted its stake in shares of QuidelOrtho by 1.3% in the 4th quarter. State Street Corp now owns 2,704,355 shares of the company’s stock valued at $77,236,000 after purchasing an additional 35,616 shares during the last quarter. Finally, Newtyn Management LLC grew its holdings in shares of QuidelOrtho by 58.3% during the 3rd quarter. Newtyn Management LLC now owns 2,700,000 shares of the company’s stock worth $79,515,000 after purchasing an additional 994,332 shares during the period. 99.00% of the stock is currently owned by institutional investors and hedge funds.
About QuidelOrtho
QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.
The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.
Featured Stories
- Five stocks we like better than QuidelOrtho
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.
